To expand the structure-activity relationships of fosmidomycin and FR900098, two potent antimalarials interfering with the MEP-pathway, we decided to replace a methylene group in β-position of the phosphonate moiety of these leads by an oxygen atom. β-oxa-FR900098 (11) proved equally active as the parent compound.
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Synthesis of β-and γ-oxa Isosteres of Fosmidomycin and FR900098 as Antimalarial Candidates
phosphate (2) . This step requires a divalent metal ion to induce partial positive charge on the C-2 carbon, allowing the C-4 atom to attack it. Several studies have been reported on the mechanism of this isomerisation step.
1 DXR is one of the enzymes involved in the MEP pathway for the biosynthesis of isoprenoids.
with a hydroxamic acid moiety, as generally found as metal-binding group in matrix metalloproteinase inhibitors. Rohmer and coworkers reported that such metal chelating group, when replacing the N-hydroxyformamido moiety of fosmidomycin, as in compound 8 or its N-methyl analogue 9, yielded potent inhibitors of DXR which were also capable to inhibit E. coli growth. 5b Poulter and Walker reported an analogue of DOXP in which the acetyl was replaced by a hydroxamic acid, but it did not inhibit the enzyme, 13 8 probably because the molecule no longer fit in the confined volume of the active site, as a consequence of its oneatom longer chain. This is consistent with the recently reported X-ray structure.
Analogues 14 and 15, which are constitutional isomers of 12 and 13, were also synthesized.
They combine a hydroxamic acid moiety with an oxygen in γ-position that could possibly mimic the C4 hydroxyl group present in the substrate, known to be involved in hydrogen bonding with Glu152, Asn227 and Lys228. 8 Prompted by the instability of phosphonic acid 13, we set out on the synthesis of its bis(pivaloyloxymethyl)ester analogue 17.
Results and discussion
Scheme 1 depicts the synthesis of analogues 10 and 11. The synthesis of the N-hydroxy carbamates 14 and 15 is depicted in Scheme 3. Treatment of dimethylhydroxyethyl phosphonate (34) with carbonyldiimidazole and benzylhydroxyl amine afforded 37. N-methylation, as described for 34, yielded 39. The benzyl protecting groups of 37 and 39 were removed by catalytic hydrogenolysis (Pd/C) to give 38 and 40. Finally, the phosphonate esters were deprotected as outlined above.
A methyl group was introduced by deprotonation of 32 with NaH in THF followed by addition of methyl iodide to give 34.
Finally, hydroxamic acid 12 and its N-methylated analogue 13 were obtained after catalytic debenzylation (Pd/C) and deprotection of the phosphonate moieties with two equivalents of bromotrimethylsilane in dichloromethane.
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The synthesis of the bis(pivaloyloxymethyl)ester of 13 from its diethyl ester 35 was realized under standard conditions.
All target compounds were tested for inhibition of recombinant E. coli DXR ( In summary, we established an efficient and reliable synthesis for β-and γ-oxa fosmidomycin analogues. Analogue 13, which combines a β-oxa modification with a hydroxamate moiety was almost as potent in inhibiting E. coli DXR as FR900098.
Experimental
Chemicals and solvents
Most chemicals were obtained from Sigma-Aldrich or Acros Organics and were used without further purification. Compound 16 was obtained as decribed earlier.
5b All reactions were carried out under inert (N 2 ) atmosphere.
Chromatography
Precoated Merck silica gel F 254 plates and precoated Macherey-Nagel (Düren, Germany) silica gel F 254 plates were used for TLC and spots were examined under UV light at 254 nm and revealed by a phosphomolybdic-cerium sulfate solution, iodine vapour or bromocresol green solution. Column chromatography was performed on ICN silica gel (63-200 μM).
Instruments and analyses
NMR spectra were obtained with a Varian Mercury 300 spectrometer. Chemical shifts are given in parts per million (ppm) (δ relative to residual solvent peak, in the case of CDCl equipped with a standard electrospray ionization (ESI) interface. Samples were infused in an acetonitrile/water (1:1) mixture at 3μL/min.
Dibenzyl hydroxymethylphosphonate (19)
Dibenzyl phosphite (20 mL, 76.27 mmol), triethylamine (10.60 mL, 76.27 
General method for synthesis of N-(benzyloxy)-N-(chloromethyl)formamide (25) and N-(benzyloxy)-N-(chloromethyl)acetamide (26)
To a cooled solution (10 °C) of 23 or 24 (2.7 mmol) in 5.5 mL of CH 2 Cl 2 was added thionyl chloride (0.55 mL, 7.5 mmol). After stirring for 30 min, the mixture was evaporated under vacuum to yield an oily residue that could be solidified by adding a drop of hexane and connecting the flask to high vacuum. In our hands it was not possible to recrystallize 26 from ethyl acetate due to hydrolysis to the alcohol 24. Therefore, 26 was directly used in the next step without further purification. The same holds for 25. 
Dibenzyl(N-(N-benzyloxyformamido)methoxy)methylphosphonic acid (27)
Dibenzyl(N-(N-benzyloxyacetamido)methoxy)methylphosphonic acid (28)
To a solution of crude 26 (~ 2.5 mmol) in 2 mL of CH 2 Cl 2 was added a solution 19 (1.46 g, 5 mmol) in 3 mL of CH 2 Cl 2 . After stirring for 16 h at room temperature the mixture was evaporated to dryness and purified by column chromatography (CH 2 Cl 2 /ethyl acetate, 2:1) to
give 28 (0.44 g, 38%) as a clear oil.
General procedure for the benzyl deprotection of 27 and 28
A solution of compound 27 or 28 (140 mg) in MeOH (3 mL) was hydrogenated at atmospheric pressure in the presence of Pd 10 wt. % on activated carbon (70 mg). After 3 h stirring the reaction mixture was filtered over a celite pad. The solvent was removed under vacuum and the crude mixture was purified by column chromatography on silica gel (CH 2 Cl 2 /MeOH 90:10). Phosphonic acids 10 and 11 were purified according to the purification of compounds 12-15 (see further). (10) 
(N-(N-hydroxyformamido)methoxy)methylphosphonic acid
Dimethyl-2-(N-hydroxy-N-methylcarbonyloxy)ethylphosphonate (40)
Benzyl deprotection of 39 was essentially performed as described for 10 and 11, yielding the title compound in 97% yield (300 mg). Esters 33, 35, 38 or 40 (0.39 mmol) were dissolved in CH 2 Cl 2 (1.1 mL) and treated dropwise with 2 eq. of TMSBr (0.77 mmol, 83 mg) under N 2 . The reaction mixture was stirred for 2 h at room temperature. After completion of the reaction the volatile compounds were removed in vacuo to give the corresponding phosphonic acids. All final compounds were purified using a preparative HPLC system on a C18 column (5μm; Phenomenex; Luna; 250 x 21.2 mm) with a linear gradient of acetonitrile in 5 mM NH 4 OAc solution over 20 min at a flow rate of 17.5 mL/min. The purity of all target compounds was assessed by analytical HPLC (5μm;
Phenomenex; C18 (2); 250 x 4.6 mm) using the same gradient at a flow rate of 1 mL/min. All final compounds were obtained as hygroscopic foams or slight yellow oils after lyophilisation.
For compounds 12 and 13, this procedure was not very efficient since the target compounds showed poor retention (elution time: 3.6 min). Nevertheless it permitted to produce a pure fraction. 
Bis(pivaloyloxymethyl)ester of 13 (17)
To a solution of 34 in CH 2 Cl 2 was added TMSBr (4eq.) dropwise at 0 °C. After one hour the icebath was removed and the mixture was stirred at rt for another five hours. All volatiles were removed under vacuum, the residual oil was redissolved in THF and treated with water .
After five minutes the solvent was evaporated and the residue was dried in vacuo overnight.
For the alkylation step, the resulting oil was dissolved in anhydrous DMF, treated with triethylamine and stirred for ten minutes. Chloromethyl pivalate was added and the mixture was stirred at 70 °C for 6.5 h, then at room temperature during the weekend. DMF was removed under reduced pressure and the residue was taken up in diethyl ether, filtered and extracted with water and saturated NaHCO 3 -solution. 
Biological assays
DOXP reductoisomerase inhibition assay
The assay was performed in a reaction mixture containing 100 mM Tris HCl (pH 7.5), 0.2 % bovine serum albumin, 1 mM MnCl 2 , 1 mM DOXP, 0.3 mM NADPH, and 1 µg/ml recombinant DOXP reductoisomerase of E. coli. The mixture without substrate was preincubated with a serial dilution of the test compounds on a 96 well plate at 30 °C for 5 min.
The compounds had been dissolved in 100 mM Tris HCl (pH 7.5) and pre-diluted to the 10-fold final concentrations on a separate plate. The reaction was started by the addition of DOXP. The decrease of absorption was monitored at 340 nm using a SpectraMax 340PC microplate reader (Molecular Devices).
In vitro culture of P. falciparum
P. falciparum parasites were cultured in RPMI 1640 medium supplemented with 10% human serum and 25 mM HEPES buffer. 18 Human erythrocytes served as host cells. For maintenance of the culture, Petri dishes with 10 cm diameter were used. Each Petri dish contained 10 ml medium with a haematocrit of 5%. The cultures were incubated at 37 °C under an atmosphere of 5% O 2 , 3% CO 2 and 92% N 2 . The medium was changed daily, and the cultures diluted at a maximal parasitaemia of 5%. The parasitaemia was checked microscopically using Giemsastained smears.
In vitro determination of antimalarial activity
For the in vitro determination of antimalarial activity a 96-well plate assay was used (Desjardins et al. 1979; Ancelin et al. 1998) . 19 To each well 0.2 ml of a suspension of P.
falciparum infected erythrocytes with 2% haematocrit and 0.4% parasitaemia were added.
Then, a serial dilution of the test compounds was prepared on the plate. After incubation for 48 h, 0.8µ Ci 
